Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08GIH
|
|||
| Former ID |
DIB012692
|
|||
| Drug Name |
NGR-hTNF
|
|||
| Synonyms |
Arenegyr; NGR-hTNF (solid tumors); Tumor necrosis factor therapy (recombinant protein), MolMed; CD13 TNF-alpha conjugate (solid tumors), MolMed; NGR-hTNF (solid tumors), MolMed; Vascular-targeted TNF (NGR-TNF), MolMed SpA; Vascular-targeted TNF (solid tumors, iv/infusion/biological therapeutic), MolMed
Click to Show/Hide
|
|||
| Indication | Colorectal cancer [ICD-11: 2B91.Z] | Phase 3 | [1] | |
| Malignant pleural mesothelioma [ICD-11: 2C26.0; ICD-9: 163] | Phase 3 | [2], [3], [4] | ||
| Company |
Molmed
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027311) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.